– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors –
– LAVA to Receive Upfront Payment of $50 Million, With Potential for Milestones of up to Approximately $650 Million and Royalties–
– Seagen also has an Option to Nominate up to Two Additional Tumor Targets for Bispecifics using LAVA’s Proprietary Gammabody™ Platform –
BOTHELL, Wash. & UTRECHT, Netherlands & PHILADELPHIA, September 26, 2022–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced preclinical asset that utilizes LAVA’s proprietary Gammabody™ technology to target epidermal growth factor receptor (EGFR)-expressing solid tumors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005204/en/
Under the terms of the agreement, Seagen will receive an exclusive global license for LAVA-1223 and pay LAVA $50 million upfront; up to approximately $650 million in potential development, regulatory and commercial milestones; and royalties ranging from the single digits to the mid-teens on future sales. The agreement also provides Seagen with the opportunity to exclusively negotiate rights to apply LAVA's proprietary Gammabody™ platform on up to two additional tumor targets.
"Seagen is committed to driving innovation to improve the lives of people with cancer, and this agreement represents the company’s entry into a novel class of therapeutics that are designed to overcome the challenges of standard T cell engagers by leveraging the activity of a distinct T cell subset," said Roger Dansey, M.D., interim CEO and Chief Medical Officer, Seagen. "This exclusive license from LAVA provides Seagen with the opportunity to harness its expertise in developing first-in-class targeted cancer therapies, along with the company’s global development and commercialization capabilities."
LAVA-1223 employs a targeted approach that is designed to amplify natural tumor recognition by directing gamma delta T cells to the EGFR+ tumor to kill target cells and trigger immune activation while minimizing impact to normal antigen-expressing tissue. Activating the adaptive immune system with this approach has the potential to provide durable immune responses with the possibility of enhancing patient survival.
"LAVA is pioneering the development of gamma delta bispecific antibodies to treat cancer, and we are pleased to work with Seagen in this pursuit. The combination of LAVA’s proprietary Gammabody platform and deep bispecific expertise, with Seagen’s leadership in developing targeted therapies for cancer and commercialization infrastructure, makes this an ideal partnership to advance novel therapies for patients," said Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics. "This agreement enables LAVA to further validate its platform in a second solid tumor product candidate, bringing us closer toward our goal of generating effective Gammabody medicines for cancer patients. We look forward to working with Seagen to develop potential next generation cancer treatments."
About LAVA-1223
LAVA-1223 is a potential first-in-class therapy designed specifically to target and activate Vγ9Vδ2 (gamma delta) T cells in the presence of epidermal growth factor receptor (EGFR)-expressing tumor cells. EGFR is a well-validated target that is over-expressed in multiple solid tumor types including colorectal cancer, lung cancer and head and neck cancer.
About Seagen
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematological malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.
Seagen Forward-Looking Statements
Certain statements made in this press release are forward-looking, such as those, among others, relating to the therapeutic potential of LAVA-1223 and the Gammabody™ platform, including possible efficacy, safety and therapeutic uses, as well as clinical development plans. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the possibility that clinical trials may fail to establish sufficient efficacy; that adverse events or safety signals may occur; that adverse regulatory actions or other setbacks could occur in clinical trials even after promising results in earlier clinical trials or preclinical studies; that setbacks in development could occur as a result of the difficulty and uncertainty of pharmaceutical product development; and other factors. More information about the risks and uncertainties faced by Seagen is contained under the caption "Risk Factors" included in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including with respect to the company’s anticipated growth and clinical development plans, including the timing of clinical trials. Words such as "anticipate," "believe," "could," "will," "may," "expect," "should," "plan," "intend," "estimate," "potential" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody™ platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. The COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity. In addition, there may be adverse effects on our business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation and hostilities between Russia and Ukraine. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005204/en/
Contacts
Seagen Contact:
For Media
David Caouette
310-430-3476
dcaouette@seagen.com
For Investors
Douglas Maffei, Ph.D.
425-527-4881
dmaffei@seagen.com
LAVA Contact:
For Investors:
ir@lavatherapeutics.com
For IR/Media
Argot Partners
212-600-1902
lava@argotpartners.com
Related Quotes
Drug companies are facing patent expirations and price pressure, but investors won’t make them pay for those problems just yet.
The electric-car startup has secured up to $100 million to fund operations after reaching a deal to resolve a governance dispute.
Yahoo Finance Live’s Brian Sozzi breaks down the stat of the day.
When you reach retirement age, Medicare insurance offers basic medical insurance protection for your health needs. However, this coverage is basic and does not cover all of the costs for covered medical services and supplies. Medicare supplemental insurance policies are … Continue reading → The post Average Cost of Medicare Supplemental Insurance appeared first on SmartAsset Blog.
Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. Alex Carchidi (Amylyx Pharmaceuticals): Amylyx is worth owning because there's a solid chance it'll soon commercialize the first treatment for amyotrophic lateral sclerosis (ALS) that prolongs survival time while also slowing the disease's progression. Its medicine, AMX0035, has been approved for sale in Canada since late July, and regulators at the U.S. Food and Drug Administration will weigh in on the company's application for commercialization on Sept. 29.
Many years ago, I gave up drinking alcohol for a month, and was so impressed with myself, I felt I’d cracked the Da Vinci Code. Of course, once the arbitrary 30 days were up, I returned immediately to my normal drinking pattern of “most nights”. I didn’t think about it again until five years ago, when a combination of nagging headaches and peri-menopausal facial flushing drove me to give up.
Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.
"I’m feeling well and symptom free," Bourla said in a statement. Bourla, 60, back in August had contacted COVID and had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid. Paxlovid is an antiviral medication that is used to treat high-risk people, such as older patients.
Quest Diagnostics has doubled the footprint and employee count at Cleveland HeartLab since acquiring the Cleveland lab test innovator in 2017.
In 2018, senior executives at one of the country’s largest nonprofit hospital chains, Providence, were frustrated. They were spending hundreds of millions of dollars providing free health care to patients. It was eating into their bottom line. The executives, led by Providence’s chief financial officer at the time, devised a solution: a program called Rev-Up. Sign up for The Morning newsletter from the New York Times Rev-Up provided Providence’s employees with a detailed playbook for wringing mo
Georgia gubernatorial candidate sparks outrage – by accurately correcting medical misconception
PCOS is a common reason why women have difficulty getting pregnant. Here are the symptoms to look out for.
Pfizer Inc Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19. "I’m feeling well and symptom free," Bourla said in a statement. Bourla, 60, back in August had contacted COVID and had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid.
Photo Illustration by Thomas Levinson/The Daily Beast/GettyScientists have identified a molecule that just loves SARS-CoV-2, the virus that causes COVID-19. It loves it so much that it “hugs” it, practically to death—binding so tightly to the virus that the virus can’t infect our cells.The discovery of this molecule, a so-called “HR2 peptide,” is a big deal. It could form the basis of a new kind of antiviral drug. One that should work not only on current variants of the novel-coronavirus, but fu
Public concern over the condition of King Charles’s swollen hands and fingers is not new. They drew attention at the funeral of his father, Prince Philip, in April last year and as far back as 1982 the then Prince wrote to a friend that the newborn Prince William had similarly sausage-like fingers.
Our hope is that we can help make the cascade of threats to your mental health a little easier to manage.
Remember the old television show “Father Knows Best”? Well, it’s back—with “Father” now being played by arrogant, far right Republican state legislators and Governor Sununu, who happily signs their intrusive, liberty-stealing legislation into law.
The recent findings of scientists from China, that drinking at least four cups of tea a day may reduce the risk of developing type 2 diabetes by 17 per cent, is welcome news for any tea drinkers among the estimated seven million people in the UK with prediabetes. But if you aren’t a tea drinker there are other simple dietary changes you can make to help regulate your blood sugar levels. Here are three…
Over 60 ready-to-eat meat products sold by one company in Illinois are being recalled due to possible listeria contamination.
The former "Girls" star and director is looking back at her 20s, when she received extensive criticism for her body while suffering with chronic pain.